ARDT · Ardent Health, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Ardent reaffirmed full-year 2026 adjusted EBITDA guidance of $485–$535M despite softer Q2 volumes, citing $25M of volume headwinds fully offset by $20–$30M from a raised IMPACT savings target (now at least $70M, up from $55M) and a payer contract renewal expected to add $5–$10M. Q2 adjusted EBITDA fell 32.3% YoY to $115M on a 2.9% decline in total surgeries, while operating cash flow jumped 67% to $197M.
- + Raised 2026 IMPACT savings target to at least $70M from $55M, including $15–$20M from workforce restructuring
- + Payer contract renewal in one market expected to add $5–$10M to 2026 adjusted EBITDA not in prior guidance
- − Q2 adjusted EBITDA declined 32.3% YoY to $115M
- − $25M volume headwind in Q2 and H2 from softer-than-expected surgeries and admissions
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted admissions | 89,326 | the three months ended June 30, 2026 filing | — |
| Adjusted admissions growth | 2.5% | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDAR non-GAAP | $156.53M | Three Months Ended June 30, 2026 filing | — |
| Admissions | 41,104 | the three months ended June 30, 2026 filing | — |
| Admissions change | 1% | the three months ended June 30, 2026 filing | — |
| Average length of stay | 4.6 | the three months ended June 30, 2026 filing | — |
| Contract labor reduction | 41.6% | the three months ended June 30, 2026 filing | — |
| Emergency room visits | 156,896 | the three months ended June 30, 2026 filing | — |
| Hospitals operated (at period end) | 30 | the three months ended June 30, 2026 filing | — |
| Inpatient surgeries | 9,106 | the three months ended June 30, 2026 filing | — |
| JV entities revenue as percentage of total revenue | 28.6% | the three months ended June 30, 2026 filing | — |
| Licensed beds (at period end) | 4,281 | the three months ended June 30, 2026 filing | — |
| Net patient service revenue per adjusted admission | $17,864 | the three months ended June 30, 2026 filing | — |
| Net patient service revenue per adjusted admission change | 3.9% | the three months ended June 30, 2026 filing | — |
| Outpatient surgeries | 22,649 | the three months ended June 30, 2026 filing | — |
| Patient days | 189,223 | the three months ended June 30, 2026 filing | — |
| Revenue from Medicaid supplemental payment programs | $197.1M | the three months ended June 30, 2026 filing | — |
| Total encounters | 1,581,207 | the three months ended June 30, 2026 filing | — |
| Total revenue related to JV entities | $464.7M | the three months ended June 30, 2026 filing | — |
| Total surgeries | 31,755 | the three months ended June 30, 2026 filing | — |
| Total surgeries change | 2.9% | the three months ended June 30, 2026 filing | — |
| Utilization of licensed beds | 49% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARDT
this stock
Ardent Health, Inc.
|
$1.46B | +19.8% | +6.0% | 18.9 | 3.2% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -7.5% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -11.9% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +29.6% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +16.4% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARDT | -3.4% | -2.2% | +13.4% | -2.2% | +19.8% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -2.2% | -1.9% | +0.4% | -1.9% | +7.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.